PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩300 per share · Prices as of the 2026-10-02 close
Vatech posted improved quarterly revenue and operating profit in the second quarter of 2026 on the back of expansion in Europe and Asia, but whether this reverses the operating margin decline seen since 2022 remains to be confirmed in coming quarters.
Q2 2026 consolidated revenue reached KRW 121.3 billion with operating profit of KRW 24.4 billion, showing quarterly improvement
Full-year 2025 revenue hit a record KRW 426.4 billion, but operating margin fell to 12.8% from 20.2% in 2022
Vatech completed CE MDR certification for its entire product lineup in H1 2026, enabling simultaneous European launch of four new premium models
European revenue expanded to roughly 31% of total sales, with double-digit growth in France, Germany, and the Czech Republic
Quarter-to-quarter net income has shown notable volatility, warranting attention to the impact of one-off items on reported results
Founded in 1992, Vatech is a specialist in digital dental imaging equipment, developing digital X-ray systems, 3D dental CT (cone-beam CT), and intraoral sensors supplied to more than 100 countries, and listed on KOSDAQ in 2006.
Its product lineup consists of 3D dental CT, 2D panoramic X-ray, and intraoral sensors plus other products; in Q2 2026 on a standalone basis, 3D CT revenue reached KRW 42.1 billion, accounting for 58.3% of total product revenue and serving as the core revenue driver. 2D X-ray and intraoral sensor/other products also posted double-digit and single-digit growth respectively, with all product categories growing evenly.
By region, Europe is the largest market at KRW 37.5 billion, representing 30.9% of total revenue, while Asia (KRW 22.3 billion) and the United States/South America also contribute to sales.
Vatech is regarded by some market observers as a leading player in global dental CT (CBCT) unit sales, with domestic competitors including Ray and DIO, and the competitive landscape is being reshaped as Graphy recently acquired a stake in Ray to combine clear aligner and 3D printing technology with dental CT and intraoral scanning capabilities.
The company launched its AI-enabled digital platform Clever One last year, expanding an integrated hardware-software diagnostic solutions business. In Europe, Vatech operates local subsidiaries in France, the UK, the Czech Republic, and Spain to pursue regional market strategies. This regional and product diversification serves to reduce dependence on any single market.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩110.6B | ₩16.9B | 15.3% |
| 2025Q3 | ₩100.1B | ₩12.4B | 12.4% |
| 2025Q4 | ₩114.4B | ₩12.3B | 10.7% |
| 2026Q1 | ₩105.2B | ₩11B | 10.5% |
| 2026Q2 | ₩121.4B | ₩24.5B | 20.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩395.1B | ₩79.6B | ₩76.9B | 20.2% | 22.0% | 40.6% |
| 2023 | ₩384.9B | ₩64B | ₩51.7B | 16.6% | 13.0% | 41.7% |
| 2024 | ₩385.2B | ₩54B | ₩55.1B | 14.0% | 12.2% | 38.2% |
| 2025 | ₩426.4B | ₩54.8B | ₩39.1B | 12.8% | 7.9% | 38.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Vatech's annual results showed a steady profitability slowdown after peaking in 2022.
From revenue of KRW 395.1 billion and operating profit of KRW 79.6 billion (20.2% margin) in 2022, profit declined first in 2023 to KRW 64.0 billion (16.6%) on revenue of KRW 384.9 billion, and in 2024 the operating margin fell further to 14.0% even as revenue was roughly flat at KRW 385.2 billion.
In 2025, revenue rose to a record KRW 426.4 billion, yet operating profit slipped slightly to KRW 54.8 billion (12.8%), and net income attributable to owners fell sharply to KRW 39.1 billion from KRW 55.1 billion in 2024, showing a divergence between revenue growth and profit trends.
On a quarterly basis, both Q3 2025 (revenue KRW 100.1 billion, operating profit KRW 12.4 billion, net income KRW 13.9 billion) and Q4 2025 (revenue KRW 114.4 billion, operating profit KRW 12.3 billion, net income KRW 5.6 billion) showed considerable net income volatility, and in Q1 2026, while revenue was KRW 105.2 billion and operating profit fell to KRW 11.0 billion — the lowest of recent quarters — net income actually rose to KRW 14.5 billion, suggesting non-operating factors had a meaningful influence.
In Q2 2026, revenue reached KRW 121.4 billion, operating profit KRW 24.5 billion (20.2% margin), and net income KRW 22.4 billion, marking a clear quarterly improvement attributed to expanded sales in Europe and Asia combined with one-off gains.
Notably, net income attributable to owners over the trailing four quarters (Q3 2025 through Q2 2026) totaled KRW 56.3 billion, already exceeding full-year 2025 net income of KRW 39.1 billion.
Whether this recovery reflects structural margin improvement or a combination of one-off items and sales mix changes will require further confirmation in upcoming quarters.
The dental radiographic imaging equipment market is growing on the back of rising demand for implant and orthodontic dental procedures, with premium product demand also increasing amid intensifying competition.
According to market forecasts, the radiographic equipment market is expected to grow at an 8.5% compound annual rate through 2030 to roughly USD 5 billion, with North America holding the largest 38.4% share and the Asia-Pacific region growing rapidly as well.
Within this trend, demand is reportedly shifting from 2D to 3D products, a transition Vatech itself referenced at a corporate briefing in May.
In Europe, the transition to the stricter CE MDR medical device regulation has weighed on the industry broadly; a study commissioned by the European Commission found that more than half of EU medical device companies scaled back their product portfolios due to the regulation's complexity.
Against this backdrop, Vatech certified its entire existing lineup along with new models in a single process, a point highlighted as differentiating it from competitors facing supply gaps from certification delays.
In Korea's digital dentistry industry, Graphy's acquisition of a controlling stake in Ray reflects attempts to strengthen competitiveness through business combination, suggesting the domestic and global competitive landscape may continue to shift.
Since dental imaging equipment replacement cycles are known to run roughly seven to ten years, some brokerage views have suggested that replacement demand centered on units sold in 2021-2022 could begin in earnest from 2028 onward.
Vatech completed CE MDR certification for its entire European product lineup in the first half of 2026, covering all three core categories — dental CT, digital panoramic X-ray, and intraoral X-ray systems — along with four new premium models slated for 2026 launch (Green X Plus, Green X 12 SE, Green X 12 Plus, Green X 21).
These new products have already obtained approvals from Korea's Ministry of Food and Drug Safety and the U.S. FDA, positioning them for simultaneous European market launch alongside production.
The company stated it plans to expand supply of large field-of-view (FOV) models favored in developed markets alongside mid- and entry-tier products tailored to regional demand in the second half, aiming to raise market share.
Expansion of the AI-based digital diagnostic platform Clever One, launched last year, along with related software, is cited as part of a strategy to grow combined hardware-software revenue through more efficient diagnostic workflows.
Brokerages have raised earnings estimates reflecting Q2 results; Daishin Securities stated in an August 12, 2026 report that it projected full-year 2026 revenue to rise 9% year-on-year to KRW 465.4 billion and operating profit to rise 12% to KRW 61.6 billion, raising its target price by 15.6% from the prior level.
This, however, represents one brokerage's projection and could change depending on actual second-half sales performance and cost variables such as foreign exchange and logistics expenses.
The company has also expressed expectations that completed CE MDR certification could positively affect business expansion in emerging markets such as Southeast Asia, the Middle East, and Latin America, where CE certification is used as a basis for domestic approval.
The current share price appears to trade at a discount to net asset value, which can be interpreted as reflecting the recent years' profit decline from the 2022 peak.
After net income fell in 2025 compared with the prior year, quarterly net income recovered quickly in the first half of 2026, accompanying an upward revision trend in market earnings estimates.
The company has a history of paying annual cash dividends, though the dividend yield itself is not large, suggesting that investment appeal centers more on the sustainability of the profit recovery than on income return.
Daishin Securities stated that it applied the upper end of the earnings multiple range seen during the 2022 profit boom when calculating its target price, implying that the multiple currently applied to the stock sits below that level.
Ultimately, the valuation trajectory appears to hinge on whether the operating margin recovers toward 2022 levels in the second half and beyond, or whether the lower margin structure of recent years becomes more entrenched.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
European revenue growth accelerated to 23.4% in Q2 2026 from 11.7% in Q1, with strong growth in France (44.2%), the Czech Republic (38.9%), and Germany (27.1%). Europe already accounts for 30.9% of total revenue, the largest region, meaning continued growth there would have an outsized impact on overall results.
Completion of CE MDR certification across the full product lineup also secures supply continuity for existing products.
Amid industrywide delays in CE MDR transition, Vatech certified its entire existing lineup along with four new 2026 models in a single process. This differentiates it from competitors experiencing new product launch delays due to certification gaps, enabling immediate European market launch for new products.
It also establishes a foundation for expansion into emerging markets that use CE certification as a basis for domestic approval.
The Q2 2026 operating margin reached 20.2%, close to the 2022 annual level, while net income rose 200.6% year-on-year. The fact that trailing four-quarter net income already exceeds full-year 2025 net income supports the direction of profit recovery.
Expanded sales of premium products such as large FOV models could contribute to a rise in average selling prices.
The operating margin declined for four consecutive years, from 20.2% in 2022 to 16.6% in 2023, 14.0% in 2024, and 12.8% in 2025. In 2025, despite record revenue, operating profit actually declined slightly, showing that revenue growth did not necessarily translate into improved profitability. Whether the Q2 2026 margin recovery represents a structural shift requires confirmation in further quarters.
From Q3 2025 through Q2 2026, net income attributable to owners fluctuated widely at KRW 13.9 billion, 5.6 billion, 14.5 billion, and 22.4 billion. Notably, in Q1 2026 operating profit was the lowest of recent quarters yet net income increased, suggesting a significant influence from non-operating factors. This volatility reduces the predictability of reported results.
In Korea's digital dentistry industry, competitors are undergoing business combinations, such as Graphy acquiring a controlling stake in Ray.
If integrated platforms combining adjacent technologies such as clear aligners, 3D printing, and intraoral scanners emerge, this could affect Vatech's relative competitive position.
In developed markets like Europe, stricter regulation is raising entry barriers for new players while also intensifying competition among existing operators.
Since Vatech generates a significant portion of revenue overseas, exchange rate fluctuations can directly affect revenue and profit. Cost variables such as logistics expenses are also cited as factors that can disrupt short-term results. Some of the quarterly net income volatility appears to stem from such non-operating factors.
CE MDR imposes stricter clinical evidence and quality management requirements than the previous European medical device directive, and a study commissioned by the European Commission found more than half of EU medical device companies scaled back product portfolios due to regulatory complexity.
While Vatech has completed certification across its entire lineup, further regulatory tightening or rising costs and time required to maintain certification could become a burden.
The dental imaging equipment market is regarded as a competitive arena with multiple global players, and in Korea, business realignments such as the Graphy-Ray combination are emerging. Intensifying competition in both premium and entry-level products could pressure average selling prices and market share.
The Q3 2026 provisional earnings release is expected around this time, and it will be important to check whether the Q2 margin recovery continues and whether European and Asian revenue growth persists.
It will be worth monitoring the actual European sales launch of new premium models such as Green X21 and whether the planned expansion of large FOV model supply is being executed.
The International Dental Show (IDS) is scheduled to be held in Cologne, providing an opportunity to gauge new product unveilings and global order momentum.
Comparing full-year revenue and operating profit against brokerage forecasts (such as Daishin Securities' projection of KRW 465.4 billion revenue and KRW 61.6 billion operating profit) will help assess progress against second-half guidance.
Vatech has shown a divergence between revenue growth and profitability improvement, with operating margin declining for four consecutive years even as 2025 revenue hit a record high, yet the first half of 2026 brought clear signs of improvement in both quarterly operating margin and net income.
This recovery appears to be underpinned by expanded sales in Europe and Asia and the business achievement of completing CE MDR certification across the entire product lineup, though the presence of one-off gains and high quarterly net income volatility make it premature to conclude a structural improvement.
With European revenue already exceeding 30% of total sales, the spread of new premium model sales and execution of the planned expansion in large FOV model supply appear to be key variables shaping future results.
On the other hand, the multi-year margin decline trend, realignment of the domestic and global competitive landscape, and cost volatility from foreign exchange and logistics remain unresolved challenges.
Before drawing conclusions, it would be prudent to monitor whether margin recovery persists and whether one-off factors recur in quarterly results from Q3 2026 onward.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.